{"id":334893,"date":"2026-11-02T14:43:24","date_gmt":"2026-11-02T09:13:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/epigral-q2-results-fy27-pat-64-crore\/"},"modified":"2026-11-02T14:43:24","modified_gmt":"2026-11-02T09:13:24","slug":"epigral-q2-results-fy27-pat-64-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/epigral-q2-results-fy27-pat-64-crore\/","title":{"rendered":"Epigral Q2 Results FY27: PAT Jumps 24.8% to Rs 64.42 Cr, Revenue Rs 745.99 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Epigral Q2 Results FY27 were declared on 2 November 2026, and the quarterly results show standalone revenue of Rs 745.99 Cr, up 27.01% from Rs 587.36 Cr a year earlier. Net profit rose 24.8% to Rs 64.42 Cr from Rs 51.62 Cr, while Operating Profit stood at Rs 136.11 Cr against Rs 131.86 Cr. The YoY growth in revenue and net profit is the headline of this filing.<\/p>\n<\/div>\n

Epigral Ltd<\/a> (EPIGRAL) Q2 Results FY27 announced on 2 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought standalone results with revenue of Rs 745.99 Cr and PAT of Rs 64.42 Cr, as filed with the NSE and BSE. Epigral Q2 Results FY27 therefore rest on a 27.01% rise in revenue and a 24.8% rise in net profit.<\/p>\n

This Epigral Q2 Results review covers the financial highlights, the business drivers, the outlook and the risks, and the results analysis begins with the headline numbers in the Financial Highlights table that follows.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n